INTRODUCTION {#s1}
============

Colorectal cancer is the third most common cancer and the fourth leading cause of cancer-related mortality worldwide \[[@R1]\]. Although the prognosis of patients with metastatic colorectal cancer (mCRC) has improved with the development of systemic chemotherapy, the median survival time is around 30 months, and this should be improved \[[@R2], [@R3]\]. Recently, two active agents (regorafenib and TAS-102) have been approved in Japan as salvage-line treatments for mCRC refractory to standard front-line chemotherapy.

Regorafenib is a multi-target tyrosine kinase inhibitor that targets angiogenic, stromal and oncogenic kinases and it was clearly demonstrated to prolong the survival duration of heavily treated mCRC patients when compared with placebo in two randomised phase III trials (CORRECT and CONCUR) \[[@R4], [@R5]\]. Regorafenib showed a disease control rate (DCR) of 41--51%. However, it caused some unfavourable side effects, such as hand-foot skin reaction, fatigue, hypertension and diarrhoea, which could worsen a patient\'s general condition and quality of life \[[@R4], [@R5]\]. Predictive markers for mCRC patients treated with regorafenib are desired, but such markers have not yet been elucidated \[[@R6]\].

The radiological changes with vascular endothelial growth factor (VEGF) pathway inhibitors have been suggested to be a surrogate for clinical activity \[[@R7], [@R8]\]. In colorectal cancer, Chun et al. reported that morphologic response (MR) based on computed tomography (CT) findings had a significant association with pathologic response and overall survival (OS) among patients with liver metastasis treated with bevacizumab-containing chemotherapy \[[@R9]\]. Furthermore, Ricotta et al. reported that cavity formation (CF) of lung metastasis on CT scans performed at the earliest post-baseline evaluation (at week 8) might predict OS and progression-free survival (PFS) in patients treated with regorafenib \[[@R10]\]. Therefore, early morphological change (EMC) might be a predictor of the outcome of patients receiving regorafenib. However, results have not been conclusive because of a small sample size and lack of validation.

Therefore, we conducted a multicenter retrospective study to investigate whether EMC can predict the outcome of mCRC patients receiving regorafenib.

RESULTS {#s2}
=======

Patient population and clinical outcomes {#s2_1}
----------------------------------------

The study evaluated 96 mCRC patients who received regorafenib. After excluding 28 patients who were not eligible (Figure [1](#F1){ref-type="fig"}), 68 patients were finally recruited in this study (analysis 1: 52 patients with lung metastasis, analysis 2: 45 patients with liver metastasis, and analysis 3: 68 patients with lung and/or liver metastases). The baseline characteristics are shown in Table [1](#T1){ref-type="table"}. Almost all patients were refractory or intolerable to standard front-line chemotherapeutic agents (fluoropyrimidine, oxaliplatin and irinotecan; 100%, bevacizumab; 99%, anti-epidermal growth factor receptor (EGFR) antibody; 88%, KRAS or RAS wild-type tumour), whereas only 22% of the patients had previously received TAS-102. In each analysis, patient characteristics between the subgroup with and that without morphological change were almost well balanced. The median (range) period between the start of regorafenib therapy and the first post-treatment CT scan was 55 (20-133) days and this was comparable between the subgroup with and that without morphological change in each analysis.

![CONSORT diagram](oncotarget-08-110530-g001){#F1}

###### Patient characteristics

                                            Cohort 1Lung metastasis   Cohort 2Liver metastasis   Cohort 3Lung and/or liver metastasis                                                                                                                                                                  
  ----------------------------------------- ------------------------- -------------------------- -------------------------------------- --------- ---------- ----------- ---------- -------- ---------- ---------- ---------- -------- --------- -------- ---- --------- ---- --------- ---- --------- --------
  Age (years)                                                                                                                                                                                                                                                                                          
   Median                                   63                        59                         0.06                                   67        63         63          0.06       63       63         61         65         0.23                                                                     
   Range                                    41-80                     43-70                      41-80                                            40-79      44-74       40-79               40-80      43-74      40-80                                                                               
  Sex                                                                                                                                                                                                                                                                                                  
   Male                                     25                        \(48\)                     5                                      \(31\)    20         \(56\)      0.14       28       \(62\)     10         \(71\)     18       \(58\)    0.51     37   \(54\)    13   \(52\)    24   \(56\)    0.80
   Female                                   27                        \(52\)                     11                                     \(69\)    16         \(44\)                 17       \(38\)     4          \(29\)     13       \(42\)             31   \(46\)    12   \(48\)    19   \(44\)    
  PS                                                                                                                                                                                                                                                                                                   
   0                                        37                        \(71\)                     12                                     \(75\)    25         \(69\)      0.77       32       \(71\)     12         \(86\)     20       \(65\)    0.18     47   \(69\)    21   \(84\)    26   \(60\)    0.12
   1                                        14                        \(27\)                     4                                      \(25\)    10         \(28\)      13         \(29\)   2          \(14\)     11         \(35\)   20        \(29\)   4    \(16\)    16   \(37\)                   
   2                                        1                         \(2\)                      0                                      \(0\)     1          \(3\)       0          \(0\)    0          \(0\)      0          \(0\)    1         \(1\)    0    \(0\)     1    \(2\)                    
  Histology                                                                                                                                                                                                                                                                                            
   Tub1                                     20                        \(38\)                     7                                      \(44\)    13         \(36\)      0.25       13       \(29\)     7          \(50\)     6        \(19\)    0.18     23   \(34\)    11   \(44\)    12   \(28\)    0.47
   Tub2                                     31                        \(60\)                     8                                      \(50\)    23         \(64\)      30         \(67\)   7          \(50\)     23         \(74\)   42        \(62\)   13   \(52\)    29   \(67\)                   
   Pap                                      0                         \(0\)                      0                                      \(0\)     0          \(0\)       1          \(2\)    0          \(0\)      1          \(3\)    1         \(1\)    0    \(0\)     1    \(2\)                    
   Unknown                                  1                         \(2\)                      1                                      \(6\)     0          \(0\)       1          \(2\)    0          \(0\)      1          \(3\)    2         \(3\)    1    \(4\)     1    \(2\)                    
  KRAS or RAS                                                                                                                                                            0.13                                                                    0.34                                                  \>0.99
   Wild type (WT)                           29                        \(56\)                     6                                      \(38\)    23         \(64\)                 27       \(60\)     10         \(71\)     17       \(55\)             41   \(60\)    15   \(60\)    26   \(60\)    
   Mutant type (MT)                         23                        \(44\)                     10                                     \(63\)    13         \(36\)                 18       \(40\)     4          \(29\)     14       \(45\)             27   \(40\)    10   \(40\)    17   \(40\)    
  Primary site                                                                                                                                                                                                                                                                                         
   Colon                                    20                        \(38\)                     5                                      \(31\)    15         \(42\)      0.60       21       \(47\)     7          \(50\)     14       \(45\)    0.28     29   \(43\)    10   \(40\)    19   \(44\)    0.83
   Rectum                                   28                        \(54\)                     9                                      \(56\)    19         \(53\)      23         \(51\)   6          \(43\)     17         \(55\)   35        \(51\)   13   \(52\)    22   \(51\)                   
   Cecum                                    4                         \(8\)                      2                                      \(13\)    2          \(6\)       1          \(2\)    1          \(7\)      0          \(0\)    4         \(6\)    2    \(8\)     2    \(5\)                    
  Primary side                                                                                                                                                                                                                                                                                         
   Left                                     41                        \(79\)                     12                                     \(75\)    29         \(81\)      0.72       36       \(80\)     10         \(71\)     26       \(84\)    0.42     52   \(76\)    19   \(76\)    33   \(77\)    \>0.99
   Right                                    11                        \(21\)                     4                                      \(25\)    7          \(19\)                 9        \(20\)     4          \(29\)     5        \(16\)             16   \(24\)    6    \(24\)    10   \(23\)    
  Primary presence                                                                                                                                                                                                                                                                                     
   Presence                                 9                         \(17\)                     3                                      \(19\)    6          \(17\)      \>0.99     10       \(22\)     3          \(21\)     7        \(23\)    \>0.99   11   \(16\)    5    \(20\)    6    \(14\)    0.52
   Absence                                  43                        \(83\)                     13                                     \(81\)    30         \(83\)                 35       \(78\)     11         \(79\)     24       \(77\)             57   \(84\)    20   \(80\)    37   \(86\)    
  Disease status                                                                                                                                                                                                                                                                                       
   Advanced                                 33                        \(64\)                     7                                      \(44\)    26         \(72\)      0.07       33       \(73\)     12         \(86\)     21       \(68\)    0.29     45   \(66\)    15   \(60\)    30   \(70\)    0.44
   Recurrent                                19                        \(36\)                     9                                      \(56\)    10         \(28\)                 12       \(27\)     2          \(14\)     10       \(32\)             23   \(34\)    10   \(40\)    13   \(30\)    
  No. of metastatic sites                                                                                                                                                                                                                                                                              
   1-2                                      24                        \(46\)                     9                                      \(56\)    15         \(42\)      0.38       26       \(58\)     10         \(71\)     16       \(52\)    0.33     37   \(54\)    15   \(60\)    22   \(51\)    0.61
   3-5                                      28                        \(54\)                     7                                      \(44\)    21         \(58\)                 19       \(42\)     4          \(29\)     15       \(48\)             31   \(46\)    10   \(40\)    21   \(49\)    
  No. of prior regimens                                                                                                                                                                                                                                                                                
   2-3                                      39                        \(75\)                     12                                     \(75\)    27         \(75\)      \>0.99     36       \(80\)     12         \(86\)     24       \(77\)    0.70     51   \(75\)    20   \(80\)    31   \(72\)    0.57
   4-5                                      13                        \(25\)                     4                                      \(25\)    9          \(25\)                 9        \(20\)     2          \(14\)     7        \(23\)             17   \(25\)    5    \(20\)    12   \(28\)    
  Prior used agents                                                                                                                                                                                                                                                                                    
   Fluoropyrimidine                         52                        \(100\)                    16                                     \(100\)   36         \(100\)     \>0.99     45       \(100\)    14         \(100\)    31       \(100\)   \>0.99   68   \(100\)   25   \(100\)   43   \(100\)   \>0.99
  Oxaliplatin                               52                        \(100\)                    16                                     \(100\)   36         \(100\)     \>0.99     45       \(100\)    14         \(100\)    31       \(100\)   \>0.99   68   \(100\)   25   \(100\)   43   \(100\)   \>0.99
   Irinotecan                               52                        \(100\)                    16                                     \(100\)   36         \(100\)     \>0.99     45       \(100\)    14         \(100\)    31       \(100\)   \>0.99   68   \(100\)   25   \(100\)   43   \(100\)   \>0.99
   Bevacizumab                              w51                       \(98\)                     16                                     \(100\)   35         \(97\)      \>0.99     45       \(100\)    14         \(100\)    31       \(100\)   \>0.99   67   \(99\)    25   \(100\)   42   \(98\)    \>0.99
   Anti-EGFR antibody (if KRAS or RAS WT)   26                        \(90\)                     5                                      \(83\)    21         \(91\)      0.52       22       \(81\)     7          \(70\)     15       \(88\)    0.28     36   \(88\)    11   \(73\)    25   \(96\)    0.05
   TAS-102                                  11                        \(21\)                     4                                      \(25\)    7          \(19\)      0.72       8        \(18\)     4          \(29\)     4        \(13\)    0.23     15   \(22\)    6    \(24\)    9    \(21\)    0.77
  Prior chemotherapy period (months)                                                                                                                                                                                                                                                                   
   Median                                   29.2                      27.3                       29.7                                   0.69      28.7       28.9        27.6       0.42     29.2       29.1       29.3       0.68                                                                     
   Range                                    6.8-85.7                  6.8-75.4                   7.3-85.7                                         6.8-85.7   18.3-76.1   6.8-85.7            6.8-85.7   6.8-76.1   7.3-85.7                                                                            
  Starting dose of regorafenib                                                                                                                                                                                                                                                                         
   160mg/day                                35                        \(67\)                     11                                     \(69\)    24         \(67\)      0.99       35       \(78\)     12         \(86\)     23       \(74\)    0.37     50   \(74\)    19   \(76\)    31   \(72\)    0.89
   120mg/day                                10                        \(19\)                     3                                      \(19\)    7          \(19\)      6          \(13\)   2          \(14\)     4          \(13\)   11        \(16\)   4    \(16\)    7    \(16\)                   
   80mg/day                                 7                         \(13\)                     2                                      \(13\)    5          \(14\)      4          \(9\)    0          \(0\)      4          \(13\)   7         \(10\)   2    \(8\)     5    \(12\)                   
  First CT evaluation (days)^\*^                                                                                                                                                                                                                                                                       
   Median                                   56                        57                         56                                     0.42      55         52          56         0.51     55         55         55         0.88                                                                     
   Range                                    25-92                     30-87                      25-92                                            20-133     28-74       20-133              20-133     28-87      20-133                                                                              

^\*^ Interval from the start of regorafenib to the first post-treatment CT scan.

Overall, median PFS and median OS were 2.8 and 7.3 months, respectively (Figure [2](#F2){ref-type="fig"}). Stable disease (SD) was noted in 34 patients (50%) and the remaining patients showed progressive disease (PD).

![Overall survival (OS) and progression-free survival (PFS) in all eligible patients (n = 68)](oncotarget-08-110530-g002){#F2}

Early morphological change {#s2_2}
--------------------------

### Analysis 1 {#s2_2_1}

Of the 52 patients in analysis 1, 16 (31%) had CF on the first post-treatment CT scan. There was no discrepancy among two evaluators with regard to the identification of CF. Among six patients with a pre-existing cavity at baseline, four experienced an increase in the pre-existing cavity. An exemplary CT image of CF is shown in Figure [3](#F3){ref-type="fig"}. PFS was significantly longer in patients with CF than in those without CF (hazard ratio \[HR\]: 0.29, 95% confidence interval \[CI\]: 0.14--0.59, p \< 0.01, median PFS: 4.2 vs. 2.4 months) (Figure [4](#F4){ref-type="fig"}). OS was also longer in patients with CF than in those without CF; however, the difference was not significant (HR: 0.56, 95% CI: 0.29--1.10, p = 0.09, median OS: 9.2 vs. 6.5 months) (Figure [4](#F4){ref-type="fig"}). The DCR was significantly higher in patients with CF than in those without CF (81% vs. 36%, p \< 0.01).

![Exemplary CT images\
Upper case: A case with cavity formation (CF). Baseline **(A)** and first post-treatment **(B)** CT showed the emergence of CF. Middle case: A typical case (without discrepancy) with active morphological response (MR). Both evaluators classified liver metastases into group 3 at baseline CT **(C)** and group 2 at first post-treatment CT **(D)**. Therefore, this patient had 'incomplete' response. Lower case: A discrepant case with active MR. At baseline CT **(E)**, both evaluators classified liver metastases into group3. At first post-treatment CT **(F)**, there was discrepancy between two evaluators (group 3 and 2), and consensus review determined group2. Therefore, this patient had 'incomplete' response.](oncotarget-08-110530-g003){#F3}

![Analysis 1 (patients with lung metastasis)\
**(A)** Progression-free survival in patients with cavity formation (CF) and those without CF **(B)** Overall survival in patients with CF and those without CF.](oncotarget-08-110530-g004){#F4}

### Analysis 2 {#s2_2_2}

Of the 45 patients in analysis 2, 39 and 6 patients were classified into groups 3 and 2, respectively, at the baseline CT scan. Among them, one patient in group 3 converted to group 1 (optimal response), 13 patients in group 3 converted to group 2 (incomplete response) and the rest did not show a group change (none) at the first post-treatment CT scan. Therefore, 14 (31%) patients had active MR. Discrepancy in grouping between the two evaluators occurred in 7 cases (16%) (5 cases included discrepancy about group 2 or 3 and 2 cases included discrepancy about group 1 or 2), but the discrepancy was resolved by consensus review. Exemplary CT images of active MR in both typical (without discrepancy) case and discrepant case are shown in Figure [3](#F3){ref-type="fig"}.

PFS was significantly longer in patients with active MR than in those without active MR (HR: 0.21, 95% CI: 0.10--0.46, p \< 0.01, median PFS: 5.3 vs. 2.4 months) (Figure [5](#F5){ref-type="fig"}). OS was also significantly longer in patients with active MR than in those without active MR (HR: 0.40, 95% CI: 0.19--0.86, p = 0.02, median OS: 13.6 vs. 6.9 months) (Figure [5](#F5){ref-type="fig"}). The DCR was significantly higher in patients with active MR than in those without active MR (100% vs. 39%, p \< 0.01).

![Analysis 2 (patients with liver metastasis)\
**(A)** Progression-free survival (PFS) in patients with active morphological response (MR) and those without active MR. **(B)** Overall survival (OS) in patients with active MR and those without active MR. **(C)** PFS in patients with an attenuation change of ≤ −22% and those with an attenuation change of \> −22%. **(D)** OS in patients with an attenuation change of ≤ −22% and those with an attenuation change of \> −22%.](oncotarget-08-110530-g005){#F5}

A total of 78 liver metastases from 45 patients were assessed for the attenuation value. The median attenuation value at baseline CT in the 45 patients was 63 Hounsfield unit (HU) (range, 26--90 HU), and the median attenuation change was −22% (range, −57 to 56). The DCR was equivalent between patients with an attenuation change of ≤ −22% (n = 23) and those with an attenuation change of \> −22% (n = 22) (65% vs. 50%, p = 0.37). Both PFS and OS were also equivalent between patients with an attenuation change of ≤ −22% and those with an attenuation change of \> −22% (Figure [5](#F5){ref-type="fig"}).

### Analysis 3 {#s2_2_3}

Of the 68 patients in analysis 3, 25 (37%) had EMC. PFS was significantly longer in patients with EMC than in those without EMC (HR: 0.16, 95% CI: 0.08--0.32, p \< 0.01, median PFS: 5.3 vs. 2.1 months) (Figure [6](#F6){ref-type="fig"}). OS was also significantly longer in patients with EMC than in those without EMC (HR: 0.39, 95% CI: 0.22--0.71, p \< 0.01, median OS: 13.3 vs. 6.1 months) (Figure [6](#F6){ref-type="fig"}). The DCR was significantly higher in patients with EMC than in those without EMC (88% vs. 28%, p \< 0.01).

![Analysis 3 (patients with lung and/or liver metastasis)\
**(A)** Progression-free survival (PFS) in patients with early morphological change (EMC) and those without EMC. **(B)** Overall survival (OS) in patients with EMC and those without EMC. **(C)** PFS in patients showing stable disease (SD) with EMC and those showing SD without EMC. **(D)** OS in patients showing SD with EMC and those showing SD without EMC.](oncotarget-08-110530-g006){#F6}

Overall, among 34 patients (34/68, 50%) who showed SD, 22 (65%) had EMC. PFS was significantly longer in these 22 patients with EMC than in 12 patients without EMC (HR: 0.20, 95% CI: 0.08--0.48, p \< 0.01, median PFS: 5.9 vs. 3.3 months) (Figure [6](#F6){ref-type="fig"}). OS was also longer in patients with EMC than in those without EMC; however, the difference was not significant (HR: 0.44, 95% CI: 0.18--1.06, p = 0.06, median OS: 13.6 vs. 11.5 months) (Figure [6](#F6){ref-type="fig"}).

DISCUSSION {#s3}
==========

This is the first study to evaluate EMC for predicting the outcome of mCRC patients treated with regorafenib. We demonstrated that the frequency of EMC was 37% and that EMC could be a positive predictor for PFS, OS and the DCR.

CF in lung lesions has been reported to be an effect of angiogenesis inhibitors in lung cancer, with a frequency of 14--24% after treatment involving combination therapy or monotherapy with antiangiogenic agents \[[@R8], [@R11], [@R12]\]. Recently, Ricotta et al. reported about this morphological change in mCRC patients receiving regorafenib in a post-hoc analysis of the CORRECT study \[[@R13]\]. They showed that CF occurred with a high frequency (38.7%) and was associated with a lower rate of PD (CF+ vs CF−: 29.3% vs. 60.9%) at 8 weeks after starting regorafenib therapy. Our study demonstrated that CF occurred in 31% of patients at the first post-treatment CT scan and was associated with a higher DCR (CF+ vs. CF−: 81% vs. 36%), and these findings are consistent with the findings in the study by Ricotta et al. Furthermore, our results suggested that CF could predict better OS and PFS in patients receiving regorafenib, which has never been reported previously.

Anti-angiogenic agents are known to cause radiological change in liver lesions \[[@R9], [@R14]\]. This change can be described by the following two parameters: heterogeneity of attenuation and definition of the tumour-liver interface. Evaluation of MR is subjective with interpretation of these radiological parameters, and the frequency of discrepancy among evaluators in scoring MR has been previously reported to be 26% \[[@R9]\]. Discrepancy occurred in 18% of cases in the current study. On the other hand, change in the CT attenuation value is an objective parameter, and previous reports have shown that HU reduction after treatment with sorafenib or sunitinib was associated with longer PFS and greater tumour shrinkage in renal cell carcinoma \[[@R15], [@R16]\]. Therefore, we evaluated both MR and the change in the attenuation value for predicting the outcome in mCRC patients treated with regorafenib. Our results suggested that 'optimal' and 'incomplete' MR well predicted better OS, PFS and the DCR in comparison with 'none' MR. However, change in the CT attenuation value was not demonstrated to be a predictor of any outcome, which is consistent with the finding in a previous report \[[@R17]\]. We speculate that MR is more representable for the anti-angiogenic effect of regorafenib than CT attenuation change, because disease progression could also lead to HU reduction through lack of blood supply and central necrosis resulting from a rapid increase in tumour volume.

We evaluated EMC as a combination of CF and MR for the prediction of outcomes in patients with lung and/or liver metastases. Our result indicated that EMC could significantly predict longer OS and PFS, and a higher DCR. Interestingly, the prediction utility of EMC was also recognised in a limited population with SD according to RECIST.

It is important to carefully consider the risk--benefit balance of chemotherapy especially in salvage-line treatment for mCRC, because a patient\'s general condition tends to get rapidly worse and post-discontinuation treatment is limited. Unnecessary continuation of regorafenib should be avoided considering patient quality of life. Therefore, our results could be helpful for early decision-making on the discontinuation of the administration of regorafenib in clinical practice. If a patient has EMC at the first post-treatment CT scan, continuation of regorafenib can be encouraged because a longer PFS and OS could be expected. Conversely, if a patient does not have EMC, discontinuation of regorafenib and change to TAS-102 or best supportive care might be considered for a balance of toxicity, general condition, preference and other such factors.

The present study has some limitations. First, this was a retrospective study with a small sample size; another large cohort study may be required to validate and generalize our results. Second, the timing to evaluate EMC was not completely uniform. Although we usually conducted CT scan every 6-8 weeks, there were some cases with shorter or longer interval between treatment initiation and first post-treatment evaluation by physician\'s discretion. Last, MR is a subjective parameter, but frequency of discrepancy among evaluators was not different among studies.

In conclusion, both CF in lung metastasis and active MR in liver metastasis could predict good outcomes in mCRC patients treated with regorafenib. EMC, as a combination parameter of CF and active MR, may be an effective marker to encourage patients and physicians or to facilitate early decision-making for the discontinuation of regorafenib in clinical practice.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

We retrospectively reviewed the records of mCRC patients who received regorafenib between January 2011 and July 2016 at St. Marianna University School of Medicine or Chiba Cancer Center, Japan. All patient data were extracted from the hospital database. The eligibility criteria were: (1) histologically proven adenocarcinoma of the colon or rectum; (2) presence of lung and/or liver metastases; (3) absence of concomitant aggressive malignant diseases; (4) presence of a refractory or intolerant condition to fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF antibody and anti-EGFR antibody for KRAS (or RAS) wild-type tumour (including non-administration of agents because of comorbidity or refusal); (5) more than two prior regimens; (6) Eastern Cooperative Oncology Group performance status (ECOG PS) of 0--2; (7) CT assessment performed at baseline and after treatment (if only liver metastasis was present without lung metastasis, contrast-enhanced CT was required at baseline and after treatment). This study was approved by the Institutional Review Board of St. Marianna University School of Medicine and Chiba Cancer Center. All procedures were in accordance with the Helsinki Declaration. All patients provided written informed consent before treatment initiation.

Chemotherapy {#s4_2}
------------

Patients orally received 160 mg of regorafenib once daily for the first 3 weeks of each 4-week session. Dose reduction, including starting dose, was allowed appropriately at the physician\'s discretion. Chemotherapy was repeated until disease progression, an unexpected serious adverse event, or patient refusal.

Imaging analysis {#s4_3}
----------------

In this study, we evaluated contrast-enhanced CT scans, with scanning in a single phase (portal venous phase) and a slice thickness of 5 mm, at both baseline and first evaluation after starting regorafenib therapy. An independent radiologist and independent oncologist blinded to the treatment outcome assessed EMC in the first post-treatment CT scan and compared the findings with those at baseline. EMC was defined as CF in lung metastasis and/or active MR in liver metastasis. CF was defined as the emergence of an air-filled cavity of ≥10% or increase in a pre-existing cavity, in at least one lung metastatic lesion. Active MR was defined as 'optimal' or 'incomplete' response, according to the criteria reported by Chun et al. in mCRC patients receiving bevacizumab \[[@R9]\]. Liver metastasis was classified into the following three groups: group 1, characterised by homogeneous attenuation with a thin, sharply defined tumour--liver interface; group 3, characterised by heterogeneous attenuation and a thick, poorly defined tumour--liver interface; and group 2, characterised by morphological features between those of groups 3 and 1. In the criteria presented by Chun et al., three types of MR were defined according to the pattern of group change from baseline to the first evaluation as follows: 'optimal' response if the group changed from 3 or 2 to 1; 'incomplete' response if the group changed from 3 to 2; and 'none' if the group did not change or increased. In cases with multiple liver metastases, MR was decided according to the dominant response pattern. If the grouping differed between the two evaluators, the group was determined by consensus review including careful discussion and fitting between them.

We also assessed the change in the CT attenuation value (Hounsfield unit \[HU\]) for liver metastasis between baseline and the first post-treatment assessment. Attenuation change was calculated as follows: attenuation change (%) = (HU~first\ post-treatment\ CT~--HU~baseline\ CT~) / HU~baseline\ CT~ × 100. For measurement in HU, a round region of interest (ROI) was placed across the maximum area in each liver metastasis, and the mean attenuation value of the ROI was measured. If a patient had multiple liver metastases, two lesions were selected in decreasing order of size, and the mean attenuation value was calculated in each patient.

Statistical analysis {#s4_4}
--------------------

We performed the following analyses: analysis 1 (included patients with lung metastasis), analysis 2 (included those with liver metastasis) and analysis 3 (included those with lung and/or liver metastases). Patient demographics were summarised by descriptive statistics. These demographics were compared between patients with and those without morphological change using Fisher\'s exact test (binary variables) or the chi-square test (ternary variables) for categorical variables and the Mann--Whitney *U* test for continuous variables.

PFS was defined as the time from initiation of regorafenib to disease progression or death from any cause, and OS was defined as the time from initiation of regorafenib to death from any cause. The cut-off date of the observation period was December 31, 2016. Patients who had no events during the observation period were censored at the last follow-up date. Both PFS and OS were compared between patients with and those without morphological change, using the log-rank test. Cox proportional hazards model was used to calculate hazard ratio (HR) and confidence interval (CI).

Tumour response was assessed using the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. Confirmation of SD required at least a 6-week interval from the start of treatment. The DCR was defined as the proportion of patients with the best response with regard to complete response, partial response, or SD. The DCR was compared between patients with and those without morphological change using Fisher\'s exact test.

In all analyses, a two-sided p-value \<0.05 was considered statistically significant. All statistical analyses were performed using StatView ver 5.0 software (SAS Institute, Cary, NC).
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EMC

:   early morphological change

CF

:   cavity formation

MR

:   morphological response

mCRC

:   metastatic colorectal cancer

CT

:   computed tomography

HU

:   Hounsfield unit

RECIST

:   Response Evaluation Criteria in Solid Tumours
